Literature DB >> 28168658

Plumbagin Prevents IL-1β-Induced Inflammatory Response in Human Osteoarthritis Chondrocytes and Prevents the Progression of Osteoarthritis in Mice.

Wenhao Zheng1, Zhenyu Tao1, Chunhui Chen1, Chuanxu Zhang1, Hui Zhang1, Xiaozhou Ying1, Hua Chen2.   

Abstract

Inflammation and inflammatory cytokines have been reported to play vital roles in the development of osteoarthritis (OA). Plumbagin, a quinonoid compound extracted from the roots of medicinal herbs of the Plumbago genus, has been reported to have anti-inflammatory effects. However, the anti-inflammatory effects of plumbagin on OA have not been reported. This study aimed to assess the effects of plumbagin on human OA chondrocytes and in a mouse model of OA induced by destabilization of the medial meniscus (DMM). In vitro, human OA chondrocytes were pretreated with plumbagin (2, 5, 10 μM) for 2 h and subsequently stimulated with IL-1β for 24 h. Production of NO, PGE2, MMP-1, MMP-3, and MMP-13 was evaluated by the Griess reagent and ELISAs. The messenger RNA (mRNA) expression of COX-2, iNOS, MMP-1, MMP-3, MMP-13, aggrecan, and collagen-II was measured by real-time PCR. The protein expression of COX-2, iNOS, p65, p-p65, IκBα, and p-IκBα was detected by Western blot. The protein expression of collagen-II was evaluated by immunofluorescence. In vivo, the severity of OA was determined by histological analysis. We found that plumbagin significantly inhibited the IL-1β-induced production of NO and PGE2; expression of COX-2, iNOS, MMP-1, MMP-3, and MMP-13; and degradation of aggrecan and collagen-II. Furthermore, plumbagin dramatically suppressed IL-1β-stimulated NF-κB activation. In vivo, treatment of plumbagin not only prevented the destruction of cartilage and the thickening of subchondral bone but also relieved synovitis in mice OA models. Taken together, these results suggest that plumbagin may be a potential agent in the treatment of OA.

Entities:  

Keywords:  IL-1β; NF-κB; chondrocytes; osteoarthritis; plumbagin

Mesh:

Substances:

Year:  2017        PMID: 28168658     DOI: 10.1007/s10753-017-0530-8

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  43 in total

Review 1.  Matrix metalloproteinases: a tail of a frog that became a prince.

Authors:  Constance E Brinckerhoff; Lynn M Matrisian
Journal:  Nat Rev Mol Cell Biol       Date:  2002-03       Impact factor: 94.444

2.  Plumbagin inhibits LPS-induced inflammation through the inactivation of the nuclear factor-kappa B and mitogen activated protein kinase signaling pathways in RAW 264.7 cells.

Authors:  Tingyu Wang; Feihua Wu; Zhigui Jin; Zanjing Zhai; Yugang Wang; Bing Tu; Wei Yan; Tingting Tang
Journal:  Food Chem Toxicol       Date:  2013-12-01       Impact factor: 6.023

3.  Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes.

Authors:  Abdelhamid Liacini; Judith Sylvester; Wen Qing Li; Muhammad Zafarullah
Journal:  Matrix Biol       Date:  2002-04       Impact factor: 11.583

4.  Osteoarthritis cartilage histopathology: grading and staging.

Authors:  K P H Pritzker; S Gay; S A Jimenez; K Ostergaard; J-P Pelletier; P A Revell; D Salter; W B van den Berg
Journal:  Osteoarthritis Cartilage       Date:  2005-10-19       Impact factor: 6.576

5.  Butein inhibits IL-1β-induced inflammatory response in human osteoarthritis chondrocytes and slows the progression of osteoarthritis in mice.

Authors:  Wenhao Zheng; Hui Zhang; Yonglong Jin; Quan Wang; Linwei Chen; Zhenhua Feng; Hua Chen; Yaosen Wu
Journal:  Int Immunopharmacol       Date:  2016-11-15       Impact factor: 4.932

6.  Antimycobacterial constituents from Juniperus procera, Ferula communis and Plumbago zeylanica and their in vitro synergistic activity with isonicotinic acid hydrazide.

Authors:  Jaber S Mossa; Farouk S El-Feraly; Ilias Muhammad
Journal:  Phytother Res       Date:  2004-11       Impact factor: 5.878

7.  Inhibition of cartilage degradation and changes in physical properties induced by IL-1beta and retinoic acid using matrix metalloproteinase inhibitors.

Authors:  L J Bonassar; J D Sandy; M W Lark; A H Plaas; E H Frank; A J Grodzinsky
Journal:  Arch Biochem Biophys       Date:  1997-08-15       Impact factor: 4.013

8.  Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage.

Authors:  Masahiko Kobayashi; Ginette R Squires; Aisha Mousa; Michael Tanzer; David J Zukor; John Antoniou; Ulrich Feige; A Robin Poole
Journal:  Arthritis Rheum       Date:  2005-01

9.  Increase of TNFα-stimulated osteoarthritic chondrocytes apoptosis and decrease of matrix metalloproteinases 9 by NF-κB inhibition.

Authors:  Yan Wang; De Ling Li; Xin Bo Zhang; Yuan Hui Duan; Zhi Hong Wu; Dong Sheng Hao; Bao Sheng Chen; Gui Xing Qiu
Journal:  Biomed Environ Sci       Date:  2013-04       Impact factor: 3.118

Review 10.  Recent advances in the understanding of molecular mechanisms of cartilage degeneration, synovitis and subchondral bone changes in osteoarthritis.

Authors:  Yingliang Wei; Lunhao Bai
Journal:  Connect Tissue Res       Date:  2016-06-10       Impact factor: 3.417

View more
  15 in total

1.  Cyclic Tensile Strain Upregulates Pro-Inflammatory Cytokine Expression Via FAK-MAPK Signaling in Chondrocytes.

Authors:  Makoto Yanoshita; Naoto Hirose; Yuki Okamoto; Chikako Sumi; Mami Takano; Sayuri Nishiyama; Yuki Asakawa-Tanne; Kayo Horie; Azusa Onishi; Yuka Yamauchi; Tomomi Mitsuyoshi; Ryo Kunimatsu; Kotaro Tanimoto
Journal:  Inflammation       Date:  2018-10       Impact factor: 4.092

2.  The attenuating effects of plumbagin on pro-inflammatory cytokine expression in LPS-activated BV-2 microglial cells.

Authors:  Samia S Messeha; Najla O Zarmouh; Patricia Mendonca; Malak G Kolta; Karam F A Soliman
Journal:  J Neuroimmunol       Date:  2017-09-20       Impact factor: 3.478

3.  Plumbagin relieves rheumatoid arthritis through nuclear factor kappa-B (NF-κB) pathway.

Authors:  Chang Shu; Jun Chen; Meiyan Lv; Yiyuan Xi; Jujia Zheng; Xiangwei Xu
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

4.  Glutamine exerts a protective effect on osteoarthritis development by inhibiting the Jun N-terminal kinase and nuclear factor kappa-B signaling pathways.

Authors:  Lin Zhong; Le Cao; Rui Song; Xue-Fei Yang; Jia-Le Li; Hai-Tao Yang; Hong-Xiang Zhou; Hai-Tao Fan
Journal:  Sci Rep       Date:  2022-07-13       Impact factor: 4.996

5.  Baicalin promotes extracellular matrix synthesis in chondrocytes via the activation of hypoxia-inducible factor-1α.

Authors:  Pengzhen Wang; Pingping Zhu; Ruijia Liu; Qingqi Meng; Siming Li
Journal:  Exp Ther Med       Date:  2020-10-15       Impact factor: 2.447

Review 6.  Current Models for Development of Disease-Modifying Osteoarthritis Drugs.

Authors:  Meagan J Makarczyk; Qi Gao; Yuchen He; Zhong Li; Michael S Gold; Mark C Hochberg; Bruce A Bunnell; Rocky S Tuan; Stuart B Goodman; Hang Lin
Journal:  Tissue Eng Part C Methods       Date:  2021-02-04       Impact factor: 3.056

Review 7.  Anticancer Effects and Mechanisms of Action of Plumbagin: Review of Research Advances.

Authors:  Zhenhua Yin; Juanjuan Zhang; Lin Chen; Qingfeng Guo; Baocheng Yang; Wei Zhang; Wenyi Kang
Journal:  Biomed Res Int       Date:  2020-12-01       Impact factor: 3.411

8.  Cangxitongbi capsule protects articular cartilage of the knee in rats by regulating ADAMTS-5.

Authors:  Xu-Yu Song; Wen-Peng Xie; Peng Zhang; Min Zhao; Rong-Xiu Bi
Journal:  Ann Transl Med       Date:  2020-11

9.  The potent anti-inflammatory effect of Guilu Erxian Glue extracts remedy joint pain and ameliorate the progression of osteoarthritis in mice.

Authors:  Yen-Jung Chou; Jiunn-Jye Chuu; Yi-Jen Peng; Yu-Hsuan Cheng; Chin-Hsien Chang; Chieh-Min Chang; Hsia-Wei Liu
Journal:  J Orthop Surg Res       Date:  2018-10-19       Impact factor: 2.359

10.  Overexpression of SOX9 alleviates the progression of human osteoarthritis in vitro and in vivo.

Authors:  Yuanming Ouyang; Wei Wang; Bing Tu; Yi Zhu; Cunyi Fan; Yanfeng Li
Journal:  Drug Des Devel Ther       Date:  2019-08-13       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.